Bioptimus Launches M-Optimus, Revolutionizing Biomedical Innovation

Bioptimus has unveiled the M-Optimus, a groundbreaking AI model designed to simulate complex biological systems. Announced on December 17, 2025, in Paris, this innovative model integrates multiple biological modalities, marking a significant advancement in the field of biomedical research and healthcare.

Traditionally, biological research has focused on isolated data types, such as genetic sequences or medical images. This fragmented approach has limited the effectiveness of healthcare delivery. M-Optimus aims to change that by providing a universal framework that models the interdependent complexities of biology, enhancing understanding across various diseases and populations.

Features of M-Optimus

The first version of M-Optimus combines various biological modalities, including hematoxylin and eosin (H&E) stained histology images, bulk RNA sequencing, spatial transcriptomics, and clinical data. This is the first AI model globally to integrate such diverse biological data at this scale. Trained on one of the world’s largest proprietary datasets, which includes millions of patients and over 50 organ types, M-Optimus promises to reshape the landscape of biomedical innovation.

The applications of this model extend across diagnostics, drug discovery, and clinical practice, representing a transformative step forward in each area. By simulating robust representations of cells, tissues, and patients, M-Optimus is set to enhance every stage of biological discovery and patient care.

Limited Access for Pioneer Partners

Bioptimus is offering early access to M-Optimus to a select group of pioneering clients. Top pharmaceutical companies are already among the initial partners, leveraging the power of this model to enhance their core research workflows. Bioptimus is inviting a limited number of forward-thinking organizations to join these leaders, allowing them to gain a competitive edge in AI-driven biological discovery.

Jean-Philippe Vert, CEO and co-founder of Bioptimus, remarked, “With M-Optimus, we have successfully assembled the first critical components of our journey to crack the code of biology by combining multiple modalities at scale. This early access program is designed to partner with first-mover companies who share our vision: to translate this raw scientific power into tangible breakthroughs that ultimately improve patient outcomes and revolutionize the delivery of healthcare.”

In addition to the launch of M-Optimus, Bioptimus continues to excel in AI models for histopathology with its H-Optimus-1. Recognized as the industry’s leading model, H-Optimus-1 is trained on millions of whole-slide images, providing best-in-class performance in cancer grading and biomarker detection. Bioptimus has partnered with Amazon SageMaker AI to facilitate broader access to this model, enabling industry players and researchers to deploy it within their secure cloud environments while ensuring data privacy.

The H-Optimus family of models has reached nearly one million downloads, underscoring its widespread adoption among top pharmaceutical companies.

Strategic Partnerships and Expert Team

Bioptimus leverages strategic partnerships with major organizations such as AWS, HuggingFace, NVIDIA, Owkin, and Proscia to enhance the utility of its models. The company’s team is composed of over 50% PhDs from prestigious institutions, including MIT, ETH, ENS, and TUM. The leadership team includes professionals from renowned organizations such as Google Brain, DeepMind, and Tempus, all working together to push the boundaries of AI-powered biological understanding.

About Bioptimus

Bioptimus is a global leader in AI biotechnology, pioneering the development of the world’s first universal foundation model for biology. By integrating advanced AI with extensive multimodal datasets, the company is establishing a cohesive framework that bridges all levels of biological understanding, from molecular interactions to patient care. The H-Optimus model is already making an impact across research, drug discovery, and clinical applications, with adoption by 12 of the top 20 pharmaceutical companies.

For further information about Bioptimus and its innovative models, visit their official website at www.bioptimus.com.